Abstract
The Von Hippel–Lindau (VHL) disease is an autosomal dominant disorder characterized by the predisposition for multiple tumors caused by germline mutations in the tumor suppressor gene VHL. This disease is associated with a high morbidity and mortality and presents a variable expression, with different phenotypes from family to family, affecting different organs during the lifetime. The main manifestations of VHL are hemangioblastomas of the central nervous system and retina, renal carcinomas and cysts, bilateral pheochromocytomas, cystic and solid tumors of the pancreas, cystadenomas of the epididymis, and endolymphatic sac tumors. The discovery of any of the syndrome components should raise suspicion of this disease and other stigmas must then be investigated. Due to the complexities associated with management of the various VHL manifestation, the diagnosis and the follow-up of this syndrome is a challenge in the clinical practice and a multidisciplinary approach is needed. The particular relevance to endocrinologists is the detection of pheochromocytomas in 35% and islet cell tumors in 17% of VHL patients, which can be associated with hypertension, hypoglycemia, cardiac arrhythmias, and carcinoid syndrome. The purpose of this review is to define the Von Hippel–Lindau syndrome addressing its clinical aspects and classification, the importance of genetic counseling and to propose a protocol for clinical follow-up.
Similar content being viewed by others
References
Rasmussen A, Alonso E, Ochoa A, De Biase I, Familiar I, Yescas P, Sosa AL, Rodriguez Y, Chavez M, Lopez-Lopez M, Bidichandani SI (2010) Uptake of genetic testing and long-term tumor surveillance in Von Hippel–Lindau disease. BMC Med Genet 11:4. doi:10.1186/1471-2350-11-4
Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA (1990) Clinical features and natural history of Von Hippel–Lindau disease. Q J Med 77(283):1151–1163
Maher ER, Neumann HP, Richard S (2011) Von Hippel–Lindau disease: a clinical and scientific review. Eur J Hum Genet 19(6):617–623. doi:10.1038/ejhg.2010.175
Friedrich CA (1999) Von Hippel–Lindau syndrome. A pleomorphic condition. Cancer 86(11 Suppl):2478–2482
Kaelin WG (2007) Von Hippel–Lindau disease. Annu Rev Pathol 2:145–173. doi:10.1146/annurev.pathol.2.010506.092049
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733):271–275. doi:10.1038/20459
Semenza GL (2011) Oxygen sensing, homeostasis, and disease. N Engl J Med 365(6):537–547. doi:10.1056/NEJMra1011165
Frew IJ, Krek W (2008) pVHL: a multipurpose adaptor protein. Sci Signal 1(24):pe30. doi:10.1126/scisignal.124pe30
Gerdes JM, Davis EE, Katsanis N (2009) The vertebrate primary cilium in development, homeostasis, and disease. Cell 137(1):32–45. doi:10.1016/j.cell.2009.03.023
Barontini M, Dahia PL (2010) VHL disease. Best Pract Res Clin Endocrinol Metab 24(3):401–413. doi:10.1016/j.beem.2010.01.002
Musacchio A, Salmon ED (2007) The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8(5):379–393. doi:10.1038/nrm2163
Thoma CR, Toso A, Gutbrodt KL, Reggi SP, Frew IJ, Schraml P, Hergovich A, Moch H, Meraldi P, Krek W (2009) VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 11(8):994–1001. doi:10.1038/ncb1912
Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) Von Hippel–Lindau disease. Lancet 361(9374):2059–2067. doi:10.1016/S0140-6736(03)13643-4
Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al (1993) Identification of the Von Hippel–Lindau disease tumor suppressor gene. Science 260(5112):1317–1320
Couch V, Lindor NM, Karnes PS, Michels VV (2000) Von Hippel–Lindau disease. Mayo Clin Proc 75(3):265–272
Nordstrom-O’Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, van Brussel A, Voest EE, Giles RH (2010) Genetic analysis of Von Hippel–Lindau disease. Hum Mutat 31(5):521–537. doi:10.1002/humu.21219
Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B (1995) Von Hippel–Lindau disease: genetic, clinical, and imaging features. Radiology 194(3):629–642
Neumann HP, Eggert HR, Scheremet R, Schumacher M, Mohadjer M, Wakhloo AK, Volk B, Hettmannsperger U, Riegler P, Schollmeyer P et al (1992) Central nervous system lesions in Von Hippel–Lindau syndrome. J Neurol Neurosurg Psychiatry 55(10):898–901
Lonser RR, Butman JA, Huntoon K, Asthagiri AR, Wu T, Bakhtian KD, Chew EY, Zhuang Z, Linehan WM, Oldfield EH (2014) Prospective natural history study of central nervous system hemangioblastomas in Von Hippel–Lindau disease. J Neurosurg 120(5):1055–1062. doi:10.3171/2014.1.JNS131431
Wiesener MS, Seyfarth M, Warnecke C, Jurgensen JS, Rosenberger C, Morgan NV, Maher ER, Frei U, Eckardt KU (2002) Paraneoplastic erythrocytosis associated with an inactivating point mutation of the Von Hippel–Lindau gene in a renal cell carcinoma. Blood 99(10):3562–3565
Asthagiri AR, Mehta GU, Zach L, Li X, Butman JA, Camphausen KA, Lonser RR (2010) Prospective evaluation of radiosurgery for hemangioblastomas in Von Hippel–Lindau disease. Neuro Oncol 12(1):80–86. doi:10.1093/neuonc/nop018
Patrice SJ, Sneed PK, Flickinger JC, Shrieve DC, Pollock BE, Alexander E 3rd, Larson DA, Kondziolka DS, Gutin PH, Wara WM, McDermott MW, Lunsford LD, Loeffler JS (1996) Radiosurgery for hemangioblastoma: results of a multiinstitutional experience. Int J Radiat Oncol Biol Phys 35(3):493–499
Wanebo JE, Lonser RR, Glenn GM, Oldfield EH (2003) The natural history of hemangioblastomas of the central nervous system in patients with Von Hippel–Lindau disease. J Neurosurg 98(1):82–94. doi:10.3171/jns.2003.98.1.0082
Huntoon K, Wu T, Elder JB, Butman JA, Chew EY, Linehan WM, Oldfield EH, Lonser RR (2016) Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in Von Hippel–Lindau disease. J Neurosurg 124(4):971–976. doi:10.3171/2015.4.JNS1533
Kreusel KM (2005) Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications. Fam Cancer 4(1):43–47. doi:10.1007/s10689-004-1327-0
Singh AD, Nouri M, Shields CL, Shields JA, Smith AF (2001) Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with Von Hippel–Lindau disease. Ophthalmology 108(10):1907–1911
Schoen MA, Shields CL, Say EA, Douglass AM, Shields JA, Jampol LM (2016) Clinically invisible retinal hemangioblastomas detected by spectral domain optical coherence tomography and fluorescein angiography in twins. Retin Cases Brief Rep. doi:10.1097/ICB.0000000000000382
Singh AD, Nouri M, Shields CL, Shields JA, Perez N (2002) Treatment of retinal capillary hemangioma. Ophthalmology 109(10):1799–1806
Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170(6 Pt 1):2163–2172. doi:10.1097/01.ju.0000096060.92397.ed
Kragel PJ, Walther MM, Pestaner JP, Filling-Katz MR (1991) Simple renal cysts, atypical renal cysts, and renal cell carcinoma in Von Hippel–Lindau disease: a lectin and immunohistochemical study in six patients. Mod Pathol 4(2):210–214
Neumann HP, Zbar B (1997) Renal cysts, renal cancer and Von Hippel–Lindau disease. Kidney Int 51(1):16–26
Montani M, Heinimann K, von Teichman A, Rudolph T, Perren A, Moch H (2010) VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in Von Hippel–Lindau disease. Am J Surg Pathol 34(6):806–815. doi:10.1097/PAS.0b013e3181ddf54d
Malek RS, Omess PJ, Benson RC Jr, Zincke H (1987) Renal cell carcinoma in Von Hippel–Lindau syndrome. Am J Med 82(2):236–238
Choyke PL, Glenn GM, Walther MM, Zbar B, Weiss GH, Alexander RB, Hayes WS, Long JP, Thakore KN, Linehan WM (1992) The natural history of renal lesions in Von Hippel–Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol 159(6):1229–1234
Nelson JB, Oyasu R, Dalton DP (1994) The clinical and pathological manifestations of renal tumors in Von Hippel–Lindau disease. J Urol 152(6 Pt 2):2221–2226
Karsdorp N, Elderson A, Wittebol-Post D, Hene RJ, Vos J, Feldberg MA, van Gils AP, Jansen-Schillhorn van Veen JM, Vroom TM, Hoppener JW et al (1994) Von Hippel–Lindau disease: new strategies in early detection and treatment. Am J Med 97(2):158–168
Chauveau D, Duvic C, Chretien Y, Paraf F, Droz D, Melki P, Helenon O, Richard S, Grunfeld JP (1996) Renal involvement in Von Hippel–Lindau disease. Kidney Int 50(3):944–951
Steinbach F, Novick AC, Zincke H, Miller DP, Williams RD, Lund G, Skinner DG, Esrig D, Richie JP, deKernion JB et al (1995) Treatment of renal cell carcinoma in Von Hippel–Lindau disease: a multicenter study. J Urol 153(6):1812–1816
Koch CA, Mauro D, Walther MM, Linehan WM, Vortmeyer AO, Jaffe R, Pacak K, Chrousos GP, Zhuang Z, Lubensky IA (2002) Pheochromocytoma in Von Hippel–Lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol 13(1):17–27
Pinato DJ, Ramachandran R, Toussi ST, Vergine M, Ngo N, Sharma R, Lloyd T, Meeran K, Palazzo F, Martin N, Khoo B, Dina R, Tan TM (2013) Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer 108(2):429–437. doi:10.1038/bjc.2012.538
Baghai M, Thompson GB, Young WF Jr, Grant CS, Michels VV, van Heerden JA (2002) Pheochromocytomas and paragangliomas in Von Hippel–Lindau disease: a role for laparoscopic and cortical-sparing surgery. Arch Surg 137(6):682–688 (discussion 688–689)
Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G (1993) Pheochromocytomas, multiple endocrine neoplasia type 2, and Von Hippel–Lindau disease. N Engl J Med 329(21):1531–1538. doi:10.1056/NEJM199311183292103
Aufforth RD, Ramakant P, Sadowski SM, Mehta A, Trebska-McGowan K, Nilubol N, Pacak K, Kebebew E (2015) Pheochromocytoma screening initiation and frequency in Von Hippel–Lindau syndrome. J Clin Endocrinol Metab 100(12):4498–4504. doi:10.1210/jc.2015-3045
Cassol C, Mete O (2015) Endocrine manifestations of Von Hippel–Lindau disease. Arch Pathol Lab Med 139(2):263–268. doi:10.5858/arpa.2013-0520-RS
Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G et al (1995) Germline mutations in the Von Hippel–Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5(1):66–75. doi:10.1002/humu.1380050109
Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Mannelli M, Goldstein DS, Linehan WM, Lenders JW, Pacak K (2001) Pheochromocytomas in Von Hippel–Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86(5):1999–2008
Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, Chaffanjon P (2004) Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol 150(5):681–686
Green JS, Bowmer MI, Johnson GJ (1986) Von Hippel–Lindau disease in a Newfoundland kindred. CMAJ 134(2):133–138, 146
Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr, Endocrine S (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(6):1915–1942. doi:10.1210/jc.2014-1498
Gaal J, van Nederveen FH, Erlic Z, Korpershoek E, Oldenburg R, Boedeker CC, Kontny U, Neumann HP, Dinjens WN, de Krijger RR (2009) Parasympathetic paragangliomas are part of the Von Hippel–Lindau syndrome. J Clin Endocrinol Metab 94(11):4367–4371. doi:10.1210/jc.2009-1479
Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, Chauveau D, Balian A, Beigelman C, O’Toole D, Bernades P, Ruszniewski P, Richard S (2000) Pancreatic involvement in Von Hippel–Lindau disease. The Groupe Francophone d’Etude de la Maladie de Von Hippel–Lindau. Gastroenterology 119(4):1087–1095
Charlesworth M, Verbeke CS, Falk GA, Walsh M, Smith AM, Morris-Stiff G (2012) Pancreatic lesions in Von Hippel–Lindau disease? A systematic review and meta-synthesis of the literature. J Gastrointest Surg 16(7):1422–1428. doi:10.1007/s11605-012-1847-0
Corcos O, Couvelard A, Giraud S, Vullierme MP, Dermot OT, Rebours V, Stievenart JL, Penfornis A, Niccoli-Sire P, Baudin E, Sauvanet A, Levy P, Ruszniewski P, Richard S, Hammel P (2008) Endocrine pancreatic tumors in Von Hippel–Lindau disease: clinical, histological, and genetic features. Pancreas 37(1):85–93. doi:10.1097/MPA.0b013e31815f394a
Mete O, Asa SL (2013) Precursor lesions of endocrine system neoplasms. Pathology 45(3):316–330. doi:10.1097/PAT.0b013e32835f45c5
Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, Choyke PL, Walther MM, Linehan WM, Zhuang Z (1998) Multiple neuroendocrine tumors of the pancreas in Von Hippel–Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153(1):223–231. doi:10.1016/S0002-9440(10)65563-0
Gucer H, Szentgyorgyi E, Ezzat S, Asa SL, Mete O (2013) Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of Von Hippel–Lindau disease. Virchows Arch 463(4):593–597. doi:10.1007/s00428-013-1465-6
Keutgen XM, Hammel P, Choyke PL, Libutti SK, Jonasch E, Kebebew E (2016) Evaluation and management of pancreatic lesions in patients with Von Hippel–Lindau disease. Nat Rev Clin Oncol 13(9):537–549. doi:10.1038/nrclinonc.2016.37
Vinik AI, Raymond E (2013) Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib. Therap Adv Gastroenterol 6(5):396–411. doi:10.1177/1756283X13493878
Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM, Middelton L, Linehan WM, Libutti SK (2007) Clinical, genetic and radiographic analysis of 108 patients with Von Hippel–Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 142(6):814–818. doi:10.1016/j.surg.2007.09.012 (discussion 818 e811–e812)
Manski TJ, Heffner DK, Glenn GM, Patronas NJ, Pikus AT, Katz D, Lebovics R, Sledjeski K, Choyke PL, Zbar B, Linehan WM, Oldfield EH (1997) Endolymphatic sac tumors. A source of morbid hearing loss in Von Hippel–Lindau disease. JAMA 277(18):1461–1466
Butman JA, Kim HJ, Baggenstos M, Ammerman JM, Dambrosia J, Patsalides A, Patronas NJ, Oldfield EH, Lonser RR (2007) Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in Von Hippel–Lindau disease. JAMA 298(1):41–48. doi:10.1001/jama.298.1.41
Hansen MR, Luxford WM (2004) Surgical outcomes in patients with endolymphatic sac tumors. Laryngoscope 114(8):1470–1474. doi:10.1097/00005537-200408000-00028
Kim HJ, Butman JA, Brewer C, Zalewski C, Vortmeyer AO, Glenn G, Oldfield EH, Lonser RR (2005) Tumors of the endolymphatic sac in patients with Von Hippel–Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg 102(3):503–512. doi:10.3171/jns.2005.102.3.0503
Safatle PP, Farage L, Sampaio A, Ferreira FA, Safatle HP, Oliveira CA, Ferrari I (2009) Endolymphatic sac tumor and Von Hippel–Lindau disease in a single family. Arq Neuropsiquiatr 67(4):1097–1099
Jagannathan J, Lonser RR, Stanger RA, Butman JA, Vortmeyer AO, Zalewski CK, Brewer C, Surowicz C, Kim HJ (2007) Cochlear implantation for hearing loss associated with bilateral endolymphatic sac tumors in Von Hippel–Lindau disease. Otol Neurotol 28(7):927–930. doi:10.1097/MAO.0b013e31805c7506
Gersell DJ, King TC (1988) Papillary cystadenoma of the mesosalpinx in Von Hippel–Lindau disease. Am J Surg Pathol 12(2):145–149
Hes FJ, Hoppener JW, Luijt RB, Lips CJ (2005) Von Hippel–Lindau disease. Hered Cancer Clin Pract 3(4):171–178. doi:10.1186/1897-4287-3-4-171
Schmid S, Gillessen S, Binet I, Brandle M, Engeler D, Greiner J, Hader C, Heinimann K, Kloos P, Krek W, Krull I, Stoeckli SJ, Sulz MC, van Leyen K, Weber J, Rothermundt C, Hundsberger T (2014) Management of Von Hippel–Lindau disease: an interdisciplinary review. Oncol Res Treat 37(12):761–771. doi:10.1159/000369362
Obradors A, Fernandez E, Rius M, Oliver-Bonet M, Martinez-Fresno M, Benet J, Navarro J (2009) Outcome of twin babies free of Von Hippel–Lindau disease after a double-factor preimplantation genetic diagnosis: monogenetic mutation analysis and comprehensive aneuploidy screening. Fertil Steril 91(3):933, e931–937. doi:10.1016/j.fertnstert.2008.11.013
Nielsen SM, Rhodes L, Blanco I, Chung WK, Eng C, Maher ER, Richard S, Giles RH (2016) Von Hippel–Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol 34(18):2172–2181. doi:10.1200/JCO.2015.65.6140
Maher ER, Bentley E, Payne SJ, Latif F, Richards FM, Chiano M, Hosoe S, Yates JR, Linehan M, Barton DE et al (1992) Presymptomatic diagnosis of Von Hippel–Lindau disease with flanking DNA markers. J Med Genet 29(12):902–905
Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working G (2015) Targeted therapy for genetic cancer syndromes: Von Hippel–Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med 19(103):109–116
Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150. doi:10.1200/JCO.2009.26.7849
Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF (2011) Pilot trial of sunitinib therapy in patients with Von Hippel–Lindau disease. Ann Oncol 22(12):2661–2666. doi:10.1093/annonc/mdr011
Kim BY, Jonasch E, McCutcheon IE (2012) Pazopanib therapy for cerebellar hemangioblastomas in Von Hippel–Lindau disease: case report. Target Oncol 7(2):145–149. doi:10.1007/s11523-012-0214-0
Hrisomalos FN, Maturi RK, Pata V (2010) Long-term use of intravitreal bevacizumab (avastin) for the treatment of Von Hippel–Lindau associated retinal hemangioblastomas. Open Ophthalmol J 4:66–69. doi:10.2174/1874364101004010066
Battelli C, Cho DC (2011) mTOR inhibitors in renal cell carcinoma. Therapy 8(4):359–367. doi:10.2217/thy.11.32
Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5(8):671–688. doi:10.1038/nrd2062
Yim KL (2012) Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors. Cancer Manag Res 4:207–214. doi:10.2147/CMAR.S25979
Acknowledgements
We are grateful to Milaydis Sosa for proofreading.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human subjects performed by any of the authors
Informed consent
No informed consent.
Grants
This study was supported by the Portuguese Foundation for Science and Technology (FCT) through a PhD grant to Sofia S. Pereira (SFRH/BD/89308/2012).
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Crespigio, J., Berbel, L.C.L., Dias, M.A. et al. Von Hippel–Lindau disease: a single gene, several hereditary tumors. J Endocrinol Invest 41, 21–31 (2018). https://doi.org/10.1007/s40618-017-0683-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-017-0683-1